Metastatic breast cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• HER2 193
• CDK4/6 49
• PIK3CA 24
• ESR1 11
• PD-L1 10
• BRCA1 2
• PI3K 13
• BRCA2 2
• PARP 7
• AKT 4
• PD-1 10
• STAT3 0
• PTEN 2
• TP53 0
• mTOR 5
• TROP2 4
• STING 0
• VEGF 4
• YAP 0
• PALB2 3
• MMP-9 0
• AR 0
• CXCR4 1
• EGFR 3
• HER3 4
• AMPK 0
• HDAC 1
• JAK 1
• CTNNB1 0
• FGFR 1
• PSMA 0
• ATM 0
• CD40 1
• EZH2 0
• FAK 0
• HIF-1 0
• MUC1 3
• PPAR 0
• BCL-2 1
• CD47 1
• COX-2 0
• ERK 0
• HSP90 0
• IGF1R 0
• IL-6 0
• MDM2 2
• MET 0
• MYC 0
• TNF 0
• B7-H3 1
• CCR5 0
• CSF1R 0
• CTLA-4 1
• JNK 0
• LAG-3 0
• MAPK 0
• NF1 0
• NRF2 0
• RANKL 0
• TIGIT 0

24 of 1,062 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK1

  Evaluating hypertension care delivery in Veterans with rheumatoid arthritis to improve cardiovascular disease prevention

  Durham Va Medical Center· Durham, United States· until Oct 2028

• NIH NIDA · UG3

  Development of a Novel Treatment for Benzodiazepine Addiction

  University of Mississippi Med Ctr· Jackson, United States· US$1,753,289 awarded in fiscal year 2026· until Aug 2028

• NIH NINR · F31

  Clarifying symptom experiences and management strategies for breast cancer survivors with cardiotoxicity: A mixed-methods analysis

  University of South Florida· Tampa, United States· US$40,326 awarded in fiscal year 2026· until Jul 2028

• NIH NIAID · R56

  Functional dissection of a novel E2 complex critical for the HPV16 life cycle

  Virginia Commonwealth University· Richmond, United States· US$768,308 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R15

  Mechanotransduction from the tumor microenvironment to the nuclear envelope protein emerin enables nuclear softening during cancer metastasis

  Rowan University· Glassboro, United States· US$564,078 awarded in fiscal year 2026· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DuoLipo-TNP: Dual-Responsive Liposome Platform for Selective Delivery of Triphosphate Nucleotide Prodrugs in Triple-Negative Breast Cancer

  Cardiff University· Cardiff, United Kingdom· EU contribution €260,348· until Apr 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Mapping antigenic niches of tumor-infiltrating B cells in triple-negative breast cancer (MAP-BC)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €252,180· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Re-wiring tumor immune-evasive plasticity with mRNA therapy (PLASTWIRE)

  Fundacio Institut Hospital del Mar D Investigacions Mediques· Barcelona, Spain· EU contribution €2,533,207· until Nov 2031

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Multispecific theranostic nano-engager platform (Nano-BITE)

  Institut Gustave Roussy· Villejuif, France· EU contribution €150,000· until May 2028

  The disease is named only in the funder's project summary, not in the title.

10 of 2,354 running projects, newest first. Listed amounts together: US$1.3bn + €289.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

  NCT04517838· Mayo Clinic· Updated 9 Nov 2026

  “Insufficient funding to complete target accrual”Registry text, quoted unchanged. Source

• Terminated

  Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

  NCT01552434· M.D. Anderson Cancer Center· Updated 5 Nov 2026

  “\< 75 % participation”Registry text, quoted unchanged. Source

• Terminated

  Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

  NCT02051218· Swiss Cancer Institute· Updated 23 Oct 2026

  “Board decision as by March 2026, the number of patients undergoing treatment decreased to around 50, from the total 1,380 patients enrolled in the trial. And due to price changes in medication”Registry text, quoted unchanged. Source

• Terminated

  Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

  NCT05335473· Henan Cancer Hospital· Updated 16 Oct 2026

  “The anticipated efficacy was not achieved; the primary objective of Stage 1 in the Simon-2 design was not met.”Registry text, quoted unchanged. Source

• Terminated

  Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

  NCT05625087· UNICANCER· Updated 14 Oct 2026

  “poor accrual”Registry text, quoted unchanged. Source

• Terminated

  A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

  NCT06568692· Processa Pharmaceuticals· Updated 6 Oct 2026

  “Business Reason”Registry text, quoted unchanged. Source

• Terminated

  Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

  NCT06505018· UNICANCER· Updated 29 Sept 2026

  “The study was terminated prematurely due to insufficient patient recruitment.”Registry text, quoted unchanged. Source

• Terminated

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· SystImmune Inc.· Updated 22 Sept 2026

  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”Registry text, quoted unchanged. Source

• Terminated

  Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

  NCT04315233· University of Utah· Updated 4 Sept 2026

  “No accrual in one year”Registry text, quoted unchanged. Source

• Terminated

  Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

  NCT05756166· Roswell Park Cancer Institute· Updated 31 Aug 2026

  “Funding ended”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

  NCT05372640· National Cancer Institute (NCI)· Source

• Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

  NCT07619534· National Cancer Institute (NCI)· Source

• Onvansertib + Paclitaxel In TNBC

  NCT05383196· Antonio Giordano, MD· Source

• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  NCT05564377· National Cancer Institute (NCI)· Source

• National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Source

• Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

  NCT05422794· National Cancer Institute (NCI)· Source

• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

  NCT04704661· National Cancer Institute (NCI)· Source

• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

  NCT03606967· National Cancer Institute (NCI)· Source

• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

  NCT04550494· National Cancer Institute (NCI)· Source

• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

  NCT04546009· Hoffmann-La Roche· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 21
• Organoids 7
• CRISPR-Cas Systems 4
• Gene Expression Profiling 63
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 3
• Exome Sequencing 5
• Proteomics 16
• Metabolomics 3
• Mass Spectrometry 1
• Flow Cytometry 9
• Immunohistochemistry 70
• Liquid Biopsy 19
• Circulating Tumor DNA 46
• Xenograft Model Antitumor Assays 109
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 64
• Machine Learning 30
• Deep Learning 23
• Cohort Studies 57
• Genome-Wide Association Study 1

• Single-cell analysis reveal cell-type-specific RNA methylation patterns in breast cancer.

  J Int Med Res, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.